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Introduction
The formation of liver cirrhosis is usually an irreversible
process from a variety of long-standing insults, such as
virus, drugs, alcohol, and others. Progression into
end-stage cirrhosis is associated with a limited survival,
and it has been a challenging issue for physicians to
develop a reliable model for predicting the outcome.
Liver transplantation is the only definite treatment
modality for patients with end-stage liver cirrhosis. A
major function of the predictive model is to accurately
assess the probability of mortality within a given time
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interval, so that a timely liver transplantation can be
performed. The Child score, which was first proposed
in the 1960s and then modified and continuously
known as the Child-Turcotte-Pugh (CTP) score (Table
1), has been developed to solve these issues.
The selection of predictors and construction of the
CTP system were empirical, and the system contains
parameters that were felt very important to affect the
outcome. Abundant studies show that it can provide
accurate prognostic information associated with
various cirrhosis-related complications and clinical
situations.1–6 Although never formally validated as a
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prognostic tool, the CTP score is useful to assess the
relative risk of mortality in patients with cirrhosis and
has been popular for the past 3 decades. However, a
major defect of the CTP system is a relatively narrow
score range from 5 to 15. While the waiting list of liver
transplantation is rapidly growing and patients on the
waiting list far outnumber the cadaveric liver donors,
the priority of patients with the same CTP score
awaiting transplantation becomes difficult to judge. A
simple first-come, first-served principle was proposed
and used in the transplantation society; however,
investigators subsequently found that patients with a
longer waiting time may actually have a less severe
degree of cirrhosis. It was later demonstrated that
waiting time is not a factor that affects survival and was
abandoned as a criterion in organ allocation.7 Another
potential inherent flaw of the CTP system is that it
contains subjective variables, including the severity of
encephalopathy and ascites, which may be greatly
influenced by personal judgment from center to center
during status interpretation. These drawbacks
compromise the fairness of organ allocation in liver
transplantation. The concept of a model for end-stage
liver disease (MELD), initiated by the Mayo Clinic
group in 2000,8 emerged and was aimed to amend
these defects.
MELD for Liver Transplantation
The MELD score was originally developed to
predict the survival after transjugular intrahepatic
portosystemic shunt (TIPS).8 The investigators found
4 variables that were independently associated with
survival in the Cox multivariate model. These predictors
are serum bilirubin and creatinine level, INR
(international normalized ratio) of prothrombin time,
and the etiology of cirrhosis (alcoholic and cholestatic
vs others). After modification by the United Network
of Organ Sharing (UNOS), the currently used MELD
equation to calculate the severity score is as follows:
9.6 × loge (creatinine mg/dL) + 3.8 × loge (bilirubin
mg/dL) + 11.2 × loge (INR) + 6.4. Minimal values are
set to 1.0 for calculation purposes. The maximal serum
creatinine level considered within the MELD score
equation is 4.0 mg/dL. This equation was tested and
adequately confirmed in a study to predict the mortality
in cirrhotic patients.9 Because donor livers are allocated
to the recipients according to the severity of underlying
disease, the UNOS has suggested using the MELD
system to prioritize adult patients on the waiting list of
transplantation. Since 2002, the liver allocation system
has changed from a status-based algorithm using CTP
and other scores, to one using a continuous MELD
severity score to prioritize adult patients on the waiting
list in the USA.10,11
A major step forward of MELD is that renal
function is included for prediction. Renal dysfunction
is a common event occurring in up to 75% of cirrhotic
patients during the course of the disease, and the
severity of cirrhosis in patients with or without
hepatocellular carcinoma (HCC) was consistently
identified as an important factor of renal insufficiency
in previous studies.12–14 In addition, a number of
studies have emphasized the influence of renal
function in the course of cirrhosis.1,8,15,16 The
occurrence of hepatorenal syndrome in cirrhotic
patients usually indicates a dismal prognosis, and
liver transplantation is the only definite treatment to
prolong survival. These lines of evidence highlight
the need to take renal function into consideration in
prognostic evaluation.
Validation and Application
The MELD scoring system has been shown to more
accurately predict 3-month mortality than the
traditional CTP system for UNOS status of 2A (CTP
score * 10 plus cirrhosis-related complications such as
active variceal hemorrhage, hepatorenal syndrome,
refractory ascites/hepatic hydrothorax, or stage 3 or 4
Table 1. The Child-Turcotte-Pugh (CTP) scoring system*
1 point 2 points 3 points
Bilirubin, mg/dL < 2 2–3 > 3
Albumin, g/dL > 3.5 2.8–3.5 < 2.8
Prothrombin time prolongation, sec < 4 4–6 > 6
Ascites None Easily controlled Poorly controlled
Encephalopthy None Grades 1–2 Grades 3–4
*CTP class: A, 5–6 points; B, 7–9 points; C, 10–15 points.
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hepatic encephalopathy) and 2B (CTP score * 10, or
score * 7 plus complications) patients in a multicenter
survey in the USA.17 Its accuracy for outcome prediction
in patients with decompensated cirrhosis has also been
confirmed in Europe.18,19 Most of these comparative
studies have adopted an approach by measuring the
concordance (c-statistic) equivalent to the area under
the receiver operating characteristic (ROC) curve for
MELD and CTP score to assess the ability for outcome
prediction. Importantly, direct evidence to support
the use of MELD is that the mortality rate on the
waiting list of liver transplantation is decreasing in the
post-MELD era.20 In addition, patient and graft survival
have remained excellent since implementation of the
MELD/PELD (pediatric end-stage liver disease)
system.21 In keeping with these studies, MELD has
achieved its primary goals by allocating cadaveric livers
to the sickest patients without compromising post-
transplantation survival.22
Although underlying chronic liver diseases may
vary in different geographical regions, MELD was
suggested as a preferred model for patients with viral
hepatitis23 or alcoholic hepatitis.24,25 The application of
the MELD system has also been shown to be a useful
model to predict the outcome in cirrhotic patients
undergoing major surgical procedures.26 The use of
the MELD system has been further extended, because
the MELD score, in combination with the current
staging system for HCC, may further enhance the
prognostic capabilities and more accurately predict
the survival for HCC patients undergoing arterial
chemoembolization.27
Although MELD has been used as the primary
reference in predicting the mortality for cirrhotic
patients, it is controversial which system is best in
different clinical conditions. The comparison of the
characteristics of CTP, MELD, and Discriminant
Function score is shown in Table 2.28 The Discriminant
Function score formula is 4.6 × (patient’s prothrombin
time (PT) – control PT) + total bilirubin (mg/dL).
This scoring system, proposed by Maddrey et al,29 is
used to assess the prognosis of patients with alcoholic
hepatitis. Alternatively, a major drawback of the CTP
system, compared to MELD, which has the advantage
of minimal variability and wide-range continuous scale,
is that it has a “ceiling effect” that may limit its
application at the population level.28 However, the
CTP system does not need logarithmic transformation
and is easy to calculate at bedside evaluation. In
addition, it contains indispensable components, such
as ascites and encephalopathy, which are considered
important prognostic predictors in cirrhotic patients.
It is still debatable whether MELD is a better tool than
the CTP system in managing patients on a daily
practice basis.
For years, liver cirrhosis has been ranked in the top
10 causes of death in Taiwan. With the increasing
experience and dedication of physicians involved in
liver transplantation, since June 2002, the Department
of Health in Taiwan has authorized a nonprofit
organization, the Organ Procurement and
Transplantation Network (OPTN), to monitor the
process of organ transplantation. Patients on the
waiting list need to undergo an independent review
process and register with the OPTN. Donor organs
are then allocated to the recipients, based on their
MELD score and source of the donor organ. Although
the actual outcome data are waiting to be seen, this
strategy allows organ allocation to be judged more
objectively and may eliminate decision bias that is
solely based on the clinician’s own experience or
preference.
Table 2. Comparison of Child-Turcotte-Pugh, MELD, and Discriminant Function score*
Child-Turcotte-Pugh MELD Discriminant Function
Indication Cirrhosis of any etiology Cirrhosis of any etiology Alcoholic hepatitis
Number of variables 5 3 2
Selection of variables Empirical Statistical Statistical
“Ceiling effect” for quantitative variables Yes No No
Variables weighted for their influence Partially Yes Yes
Needs logarithmic transformation No Yes No
Needs computation No Yes Yes
Variables influenced by personal assessment Yes No No
Type of score Discrete Continuous Continuous
*Modified from Durand and Valla.28
MELD = model for end-stage liver disease.
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Limitations of MELD
Although the application of MELD provides a clear
advantage in the process of fair organ allocation, some
controversial issues arise. Patients with HCC who
fulfill the Milan criteria (1 nodule ) 5 cm in diameter,
or ) 3 nodules and ) 3 cm in diameter) are indicated
for liver transplantation;30 however, the optimal MELD
score for these patients is unclear. The UNOS has
arbitrarily assigned a fixed MELD score to prioritize
these patients on the waiting list. A higher MELD
score may shorten the waiting time and decrease the
dropout rate of HCC patients, but could increase the
risk of mortality in cirrhotic patients with a relatively
lower score on the waiting list.31 On the other hand, a
lower MELD priority score for HCC patients may
result in an increased dropout rate of HCC patients
and a subsequent increased risk of death. A recent
study has suggested a lower MELD score, especially
for T1 stage HCC (tumor size < 2 cm), for these
patients to be equivalent to the risk of short- and mid-
term mortality in the cirrhosis group, provided these
HCC patients can be treated with effective loco-
regional therapy.32 The justification of the optimal
MELD score in HCC patients may be especially
helpful for areas where liver transplantation is a common
indication for HCC.
Another intrinsic defect of MELD is that some
important parameters, such as hepatic encephalopathy,
esophageal variceal bleeding, and spontaneous bacterial
peritonitis, which are common adverse complications
in cirrhosis, are not included in MELD.33 The
occurrence of these complications indicates a status of
ongoing deterioration of residual liver function that
precedes the development of eventual hepatic failure.
There is evidence to show that patients with these
complications may not have a higher baseline MELD,
which is necessary to prioritize them on the waiting
list, and could potentially be missed during organ
allocation in the MELD era.34 In keeping with this
notion, the existence of ascites and hepatic
encephalopathy did not correlate with the MELD
score,35 and it would be quite difficult to determine the
priority of a patient with cirrhosis-related complications
and a low MELD score. There is another study to
indicate that MELD has a better performance only in
a subset of patients with higher MELD scores.36 The
outcome in patients with lower range MELD scores
cannot reliably be predicted solely with their MELD
scores, and alternative prognostic markers should be
used in conjunction to enhance the predictive accuracy.
Cirrhotic patients tend to have dilutional
hyponatremia because of altered vascular hemodynamics.
Serum sodium level has recently been shown as an
independent prognostic predictor in patients with
advanced cirrhosis.37–39 A serum sodium level less than
126 mEq/L at listing for transplantation is a strong
independent predictor of mortality, and addition of
serum sodium to MELD increases the ability to predict
short-term mortality in patients with cirrhosis.37 This
finding is largely supported by 2 other studies that
evaluated the prognostic value of serum sodium.38,39
The incorporation of serum sodium into the prognostic
model is currently being evaluated by the transplantation
community to further assess its predictive value.
Given that MELD is an established prognostic
system for end-stage liver disease, there is a concern
that a single-point determination of the score may not
be able to adequately differentiate the degree of urgency
for transplantation. The change of MELD score over
time (6MELD) was reported to more accurately predict
the survival in cirrhotic patients awaiting liver
transplantation.40,41 However, the prognostic value of
6MELD has not fully been confirmed in another study
and deserves further studies for clarification.42 These
studies add to the ongoing debate about the clinical
application of MELD, which seems to be still far from
a conclusion.
Summary and Perspectives
The MELD scoring system has become the prevailing
criterion for donor liver allocation. There is increasing
interest in the related field of MELD to investigate its
usefulness and application in liver transplantation.
Whereas early results support its apparent advantages,
the optimal role of MELD in the setting of outcome
assessment needs more studies to justify this system,
and it is still not the time to abandon the CTP system,
which clearly has a solid foundation in differentiating
the severity of liver diseases. Since the clinical scenario
of patients with early- to late-stage cirrhosis may vary
widely, appropriate modifications and fine tuning of
MELD are necessary in determining the ranking status
of patients on the waiting list, in order to avoid  futile
transplantations. The mortality of patients on the
waiting list and survival data in the pre- and post-
MELD era should be analyzed to confirm the
prognostic value of MELD. The consensus in organ
allocation for cirrhotic patients is urgently needed,
especially for areas where MELD has not been adopted
as the primary allocation reference. Before these
guidelines are agreed upon, medical practice should,
nevertheless, be based on currently available outcome
data.
MELD in liver transplantation
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